Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

  • Xingjun Yao
  • Gang Zhao
  • Hongfa Yang
  • Xinyu Hong
  • Li Bie
  • Guojin Liu
Original Paper

Abstract

Purpose

High-mobility group box 1 (HMGB1) has been implicated in a variety of biologically important processes, including transcription, DNA repair, V(D)J recombination, differentiation, development, and extracellular signaling. The increased expression of HMGB1 has been described in colorectal cancer (CRC). However, there is no report about the correlation of HMGB1 with clinicopathologic features, including the survival of patients with CRC.

Methods

In present study, we investigated HMGB1 expression and its prognostic significance in CRC by performing immunohistochemical analysis, using a total of 192 paraffin-embedded archival CRC samples. Moreover, disruption of endogenous HMGB1 protein through a siRNA knockdown technique was performed to investigate the possible role of HMGB1 in the process of tumor invasion and metastasis.

Results

Overexpression of HMGB1 was shown in 55.7% cases. Statistical analysis showed that HMGB1 expression was positively correlated with tumor invasion (P = 0.048), lymph node metastasis (P = 0.011), distant metastasis (P = 0.031), and Duke’s stage (P = 0.029) of CRC patients. Patients with higher HMGB1 expression had shorter overall survival time, whereas patients with lower level of HMGB1 had better survival. Multivariate analysis suggested that HMGB1 expression might be an independent prognostic indicator for the survival of patients with CRC. Disruption of endogenous HMGB1 protein through a siRNA knockdown technique was shown to suppress substantially the invasion ability of SW620 cells.

Conclusions

Our results suggest that HMGB1 protein is a valuable marker for progression of CRC patients. High HMGB1 expression is associated with poor overall survival in patients with CRC.

Keywords

HMGB1 Progression Prognosis Colorectal cancer 

References

  1. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO, Kim H (2003) Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63:2188–2193PubMedGoogle Scholar
  2. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38CrossRefPubMedGoogle Scholar
  3. Czura CJ, Wang H, Tracey KJ (2001) Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 7:315–321CrossRefPubMedGoogle Scholar
  4. Gutman M, Fidler IJ (1995) Biology of human colon cancer metastasis. World J Surg 19:226–234CrossRefPubMedGoogle Scholar
  5. Huttunen HJ, Fages C, Rauvala H (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274:19919–19924CrossRefPubMedGoogle Scholar
  6. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64:92–100CrossRefPubMedGoogle Scholar
  7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130CrossRefPubMedGoogle Scholar
  8. Jeon GA, Lee JS, Patel V, Gutkind JS, Thorgeirsson SS, Kim EC, Chu IS, Amornphimoltham P, Park MH (2004) Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 112:249–258CrossRefPubMedGoogle Scholar
  9. Kuniyasu H, Chihara Y, Takahashi T (2003a) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10:445–448PubMedGoogle Scholar
  10. Kuniyasu H, Chihara Y, Kondo H (2003b) Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104:722–727CrossRefPubMedGoogle Scholar
  11. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342CrossRefPubMedGoogle Scholar
  12. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064–4068PubMedGoogle Scholar
  13. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J (2008) Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49:1184–1189CrossRefPubMedGoogle Scholar
  14. Naghavi MH, Nowak P, Andersson J, Sonnerborg A, Yang H, Tracey KJ, Vahlne A (2003) Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology 314:179–189CrossRefPubMedGoogle Scholar
  15. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164:441–449CrossRefPubMedGoogle Scholar
  16. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195CrossRefPubMedGoogle Scholar
  17. Sharma A, Ray R, Rajeswari MR (2008) Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 26:843–851CrossRefPubMedGoogle Scholar
  18. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K (2004) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10:8465–8471CrossRefPubMedGoogle Scholar
  19. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, Joos S, Zornig M (2006) Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55:234–242CrossRefPubMedGoogle Scholar
  20. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251CrossRefPubMedGoogle Scholar
  21. Wu D, Ding Y, Wang S, Zhang Q, Liu L (2008) Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216:167–175CrossRefPubMedGoogle Scholar
  22. You WC, Jin F, Devesa S, Gridley G, Schatzkin A, Yang G, Rosenberg P, Xiang YB, Hu YR, Li Q (2002) Rapid increase in colorectal cancer rates in urban Shanghai, 1972–97, in relation to dietary changes. J Cancer Epidemiol Prev 7:143–146PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Xingjun Yao
    • 1
  • Gang Zhao
    • 1
  • Hongfa Yang
    • 1
  • Xinyu Hong
    • 1
  • Li Bie
    • 1
  • Guojin Liu
    • 1
  1. 1.Department of SurgeryThe First Affiliated Hospital of Jilin UniversityChangchunPeople’s Republic of China

Personalised recommendations